- Details
- Sam Chang host Paul Crispen to discuss his study on BCG efficacy in patients with upper tract urothelial carcinoma following nephroureterectomy. Dr. Crispen discusses the findings, which show that patients with a history of upper tract disease experience bladder tumor recurrences sooner than those with primary bladder tumors, despite similar overall recurrence rates. The study reveals a higher ris...
|
- Details
- Kriti Mittal and Guru Sonpavde discuss advancements in the treatment of non-muscle invasive bladder cancer. Dr. Mittal highlights the FDA's 2020 approval of pembrolizumab for high-risk, BCG-unresponsive cases, based on the KEYNOTE-057 study. This study demonstrated a notable clinical response at three and twelve months. Atezolizumab, although showing some response, didn't meet its threshold in a s...
|
- Details
- During the State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) multidisciplinary symposium held at the 2023 Meeting of the New England Section of the AUA Kriti Mittal opens the symposium organized in partnership with the Bladder Cancer Advocacy Network and supported by Pfizer, the event features a panel of experts from various institutions. This video is part of the...
|
- Details
- During the State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) multidisciplinary symposium held at the 2023 Meeting of the New England Section of the AUA Matthew Mossanen presents a case study of a 46-year-old patient with a history of heavy smoking and other comorbidities. The patient underwent treatment with cisplatin and etoposide, followed by imaging and an even...
|
- Details
- During the State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) multidisciplinary symposium held at the 2023 Meeting of the New England Section of the AUA Matthew Mossanen led a detailed discussion and experts delved into the complexities of treating high-risk non-muscle invasive bladder cancer, focusing on BCG-unresponsive and BCG-refractory cases. Dr. Mossanen pres...
|
- Details
- During the State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) multidisciplinary symposium held at the 2023 Meeting of the New England Section of the AUA Kent Mouw discusses the evolving role of radiation in treating non-muscle invasive bladder cancer, emphasizing that there's no standard role for definitive radiation yet. He presents data from various trials, inclu...
|
- Details
- During the State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) multidisciplinary symposium held at the 2023 Meeting of the New England Section of the AUA Kriti Mittal presents the case of a 74-year-old male with persistent high-grade urothelial carcinoma in-situ (CIS) despite multiple treatments, including BCG, valrubicin, and pembrolizumab. She transitions into dis...
|
- Details
- During the State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) multidisciplinary symposium held at the 2023 Meeting of the New England Section of the AUA Laura Wood delves into the complexities of managing immune-related adverse events (irAEs) in patients undergoing checkpoint inhibitor therapy. She emphasizes the importance of early identification and effective man...
|
- Details
- During the State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) multidisciplinary symposium held at the 2023 Meeting of the New England Section of the AUA Guru Sonpavde provides a comprehensive overview of emerging agents for non-muscle invasive bladder cancer, highlighting both successes and challenges. He discusses a small phase one trial of intravesical pembrolizu...
|
